We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.
This masterclass will address a central theme in the field of airway diseases. The advent of biologics has expanded the therapeutic field for patients with asthma and CRSwNP and has also led to a significant revision in the perspectives of care. The most recent international guidelines no longer refer to the achievement of disease control, but rather to the attainment of remission or even cure.
In this CME-accredited masterclass, EUFOREA will present the latest advances, target goals and unmet needs, focusing on the future of airway disease management.
Did you miss the live session? Click the button below to access the on-demand version of this masterclass for free!
The Remission in Asthma & CRSwNP Masterclass Virtual, Belgium, 15/11/2024 - 15/11/2024 organized by The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 1.0 European CME credits (ECMEC®s). Each medical specialist should claim only those credits that he/she actually spent on the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at https://edhub.ama-assn.org/pages/applications.
Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Information regarding the conversion of EACCME® credits
Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at https://edhub.ama-assn.org/pages/applications to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA.
For other countries, please contact the relevant national/regional accreditation authority.
© All rights reserved. EUFOREA – European Forum for Research and Education in Allergy and Airway Diseases.
